Cargando…
Esophageal squamous cell carcinoma and prognosis in Taiwan
The prognosis of esophageal squamous cell carcinoma is poor. In order to find out appropriate treatment for each group of patients, we aim to examine the prognostic factors influencing survival for esophageal cancer patients in Taiwan. Data were obtained from the Taiwan Society of Cancer Registry. T...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143926/ https://www.ncbi.nlm.nih.gov/pubmed/30047253 http://dx.doi.org/10.1002/cam4.1499 |
_version_ | 1783356065631436800 |
---|---|
author | Cheng, Ya‐Fu Chen, Hui‐Shan Wu, Shiao‐Chi Chen, Heng‐Chung Hung, Wei‐Heng Lin, Ching‐Hsiung Wang, Bing‐Yen |
author_facet | Cheng, Ya‐Fu Chen, Hui‐Shan Wu, Shiao‐Chi Chen, Heng‐Chung Hung, Wei‐Heng Lin, Ching‐Hsiung Wang, Bing‐Yen |
author_sort | Cheng, Ya‐Fu |
collection | PubMed |
description | The prognosis of esophageal squamous cell carcinoma is poor. In order to find out appropriate treatment for each group of patients, we aim to examine the prognostic factors influencing survival for esophageal cancer patients in Taiwan. Data were obtained from the Taiwan Society of Cancer Registry. There were 14,394 esophageal cancer patients analyzed between 2008 and 2014 in this retrospective review. The impact of the clinicopathologic factors on overall survival was assessed. The following clinic‐pathologic factors were included to analyses: age, sex, tumor location, tumor length, histologic grade, clinical T, clinical N, clinical M, clinical stage, and all therapeutic methods within 3 months after diagnosis. The 5‐year survival rate was 16.8%, with a median survival of 343 days. The distribution of patients by their clinical stage is as follows: stage 0 (n = 162; 1.1%); stage I (n = 964; 6.7%); stage II (n = 2392; 16.6%); stage III (n = 6636; 46.1%); and stage IV (n = 3661; 25.4%). In the multivariate analysis, age, sex, tumor location, tumor length, clinical T, clinical N, clinical M, and treatment remained independent prognostic factors. Our data indicated that age, sex, tumor location, tumor length, clinical T, clinical N, clinical M, and treatment remained independent prognostic factors. Patients who could receive surgery had significantly better outcomes. |
format | Online Article Text |
id | pubmed-6143926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61439262018-09-24 Esophageal squamous cell carcinoma and prognosis in Taiwan Cheng, Ya‐Fu Chen, Hui‐Shan Wu, Shiao‐Chi Chen, Heng‐Chung Hung, Wei‐Heng Lin, Ching‐Hsiung Wang, Bing‐Yen Cancer Med Clinical Cancer Research The prognosis of esophageal squamous cell carcinoma is poor. In order to find out appropriate treatment for each group of patients, we aim to examine the prognostic factors influencing survival for esophageal cancer patients in Taiwan. Data were obtained from the Taiwan Society of Cancer Registry. There were 14,394 esophageal cancer patients analyzed between 2008 and 2014 in this retrospective review. The impact of the clinicopathologic factors on overall survival was assessed. The following clinic‐pathologic factors were included to analyses: age, sex, tumor location, tumor length, histologic grade, clinical T, clinical N, clinical M, clinical stage, and all therapeutic methods within 3 months after diagnosis. The 5‐year survival rate was 16.8%, with a median survival of 343 days. The distribution of patients by their clinical stage is as follows: stage 0 (n = 162; 1.1%); stage I (n = 964; 6.7%); stage II (n = 2392; 16.6%); stage III (n = 6636; 46.1%); and stage IV (n = 3661; 25.4%). In the multivariate analysis, age, sex, tumor location, tumor length, clinical T, clinical N, clinical M, and treatment remained independent prognostic factors. Our data indicated that age, sex, tumor location, tumor length, clinical T, clinical N, clinical M, and treatment remained independent prognostic factors. Patients who could receive surgery had significantly better outcomes. John Wiley and Sons Inc. 2018-07-25 /pmc/articles/PMC6143926/ /pubmed/30047253 http://dx.doi.org/10.1002/cam4.1499 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Cheng, Ya‐Fu Chen, Hui‐Shan Wu, Shiao‐Chi Chen, Heng‐Chung Hung, Wei‐Heng Lin, Ching‐Hsiung Wang, Bing‐Yen Esophageal squamous cell carcinoma and prognosis in Taiwan |
title | Esophageal squamous cell carcinoma and prognosis in Taiwan |
title_full | Esophageal squamous cell carcinoma and prognosis in Taiwan |
title_fullStr | Esophageal squamous cell carcinoma and prognosis in Taiwan |
title_full_unstemmed | Esophageal squamous cell carcinoma and prognosis in Taiwan |
title_short | Esophageal squamous cell carcinoma and prognosis in Taiwan |
title_sort | esophageal squamous cell carcinoma and prognosis in taiwan |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143926/ https://www.ncbi.nlm.nih.gov/pubmed/30047253 http://dx.doi.org/10.1002/cam4.1499 |
work_keys_str_mv | AT chengyafu esophagealsquamouscellcarcinomaandprognosisintaiwan AT chenhuishan esophagealsquamouscellcarcinomaandprognosisintaiwan AT wushiaochi esophagealsquamouscellcarcinomaandprognosisintaiwan AT chenhengchung esophagealsquamouscellcarcinomaandprognosisintaiwan AT hungweiheng esophagealsquamouscellcarcinomaandprognosisintaiwan AT linchinghsiung esophagealsquamouscellcarcinomaandprognosisintaiwan AT wangbingyen esophagealsquamouscellcarcinomaandprognosisintaiwan |